ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
sarge22
|
1.1K |
277K |
5 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
1.1K
|
277K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Mainstream media is GO
|
|
sarge22
|
31 |
10K |
4 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
31
|
10K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Mainstream media is GO
|
|
sarge22
|
31 |
10K |
3 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
31
|
10K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Mainstream media is GO
|
|
sarge22
|
31 |
10K |
11 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
31
|
10K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
sarge22
|
196 |
35K |
3 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
196
|
35K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
sarge22
|
196 |
35K |
3 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
196
|
35K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Singapore Healthcare Day Presentation
|
|
sarge22
|
63 |
16K |
7 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
63
|
16K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
sarge22
|
311 |
75K |
9 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
311
|
75K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
sarge22
|
1.1K |
277K |
3 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.1K
|
277K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
sarge22
|
1.1K |
277K |
1 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.1K
|
277K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
sarge22
|
114 |
32K |
3 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
114
|
32K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive Phase 1 MEND Study Top-Line Results
|
|
sarge22
|
152 |
45K |
15 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
152
|
45K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive Phase 1 MEND Study Top-Line Results
|
|
sarge22
|
152 |
45K |
11 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
152
|
45K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive Phase 1 MEND Study Top-Line Results
|
|
sarge22
|
152 |
45K |
5 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
152
|
45K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive Phase 1 MEND Study Top-Line Results
|
|
sarge22
|
152 |
45K |
20 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
152
|
45K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
sarge22
|
209 |
48K |
7 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
209
|
48K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
sarge22
|
209 |
48K |
5 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
209
|
48K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
sarge22
|
209 |
48K |
1 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
209
|
48K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor webinar - Phase 1 MND Study Top-Line Results
|
|
sarge22
|
209 |
48K |
11 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
209
|
48K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
sarge22
|
311 |
75K |
7 |
25/02/24 |
25/02/24 |
ASX - By Stock
|
311
|
75K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
sarge22
|
1.1K |
277K |
9 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
1.1K
|
277K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Ethics Committee Approval for Open-Label MND Extension Study
|
|
sarge22
|
23 |
6.9K |
20 |
30/01/24 |
30/01/24 |
ASX - By Stock
|
23
|
6.9K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Options Offer to Existing Listed Option Holders
|
|
sarge22
|
79 |
16K |
5 |
19/10/23 |
19/10/23 |
ASX - By Stock
|
79
|
16K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Options Offer to Existing Listed Option Holders
|
|
sarge22
|
79 |
16K |
13 |
19/10/23 |
19/10/23 |
ASX - By Stock
|
79
|
16K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final MND Patient in Cohort 4 Successfully Completes Dosing
|
|
sarge22
|
125 |
24K |
7 |
14/10/23 |
14/10/23 |
ASX - By Stock
|
125
|
24K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Oncology Data Supports Progression to Registration
|
|
sarge22
|
91 |
18K |
2 |
10/10/23 |
10/10/23 |
ASX - By Stock
|
91
|
18K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Oncology Data Supports Progression to Registration
|
|
sarge22
|
91 |
18K |
3 |
10/10/23 |
10/10/23 |
ASX - By Stock
|
91
|
18K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
sarge22
|
380 |
83K |
8 |
27/09/23 |
27/09/23 |
ASX - By Stock
|
380
|
83K
|
8
|
|
Charts
|
PAA Biotech |
Re:
Mr Michael Thurn CEO Interview On Small Caps
|
|
sarge22
|
57 |
15K |
5 |
21/09/23 |
21/09/23 |
Charts
|
57
|
15K
|
5
|
|
Charts
|
PAA Biotech |
Re:
Mr Michael Thurn CEO Interview On Small Caps
|
|
sarge22
|
57 |
15K |
7 |
21/09/23 |
21/09/23 |
Charts
|
57
|
15K
|
7
|
|
Charts
|
PAA Biotech |
Re:
Mr Michael Thurn CEO Interview On Small Caps
|
|
sarge22
|
57 |
15K |
10 |
21/09/23 |
21/09/23 |
Charts
|
57
|
15K
|
10
|
|
Charts
|
PAA Biotech |
Re:
Mr Michael Thurn CEO Interview On Small Caps
|
|
sarge22
|
57 |
15K |
16 |
21/09/23 |
21/09/23 |
Charts
|
57
|
15K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
sarge22
|
380 |
83K |
9 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
380
|
83K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
sarge22
|
380 |
83K |
7 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
380
|
83K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Who wants a Zoom Meeting with Management
|
|
sarge22
|
28 |
4.9K |
23 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
28
|
4.9K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Who wants a Zoom Meeting with Management
|
|
sarge22
|
28 |
4.9K |
11 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
28
|
4.9K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Who wants a Zoom Meeting with Management
|
|
sarge22
|
28 |
4.9K |
4 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
28
|
4.9K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
sarge22
|
380 |
83K |
12 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
380
|
83K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
sarge22
|
78 |
20K |
1 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
78
|
20K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
August , September , OPTOBER ,PAA
|
|
sarge22
|
144 |
29K |
4 |
09/08/23 |
09/08/23 |
ASX - By Stock
|
144
|
29K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
August , September , OPTOBER ,PAA
|
|
sarge22
|
144 |
29K |
3 |
09/08/23 |
09/08/23 |
ASX - By Stock
|
144
|
29K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
sarge22
|
218 |
49K |
4 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
218
|
49K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
sarge22
|
218 |
49K |
23 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
218
|
49K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
sarge22
|
218 |
49K |
8 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
218
|
49K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
sarge22
|
218 |
49K |
17 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
218
|
49K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
sarge22
|
218 |
49K |
6 |
06/08/23 |
06/08/23 |
ASX - By Stock
|
218
|
49K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
sarge22
|
218 |
49K |
10 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
218
|
49K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
sarge22
|
218 |
49K |
12 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
218
|
49K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
sarge22
|
396 |
82K |
7 |
27/07/23 |
27/07/23 |
ASX - By Stock
|
396
|
82K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Canine Trial Update
|
|
sarge22
|
126 |
28K |
5 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
126
|
28K
|
5
|
|